NeuroSense Therapeutics (NRSN) Registration Filing summary

Company overview and business model

• Clinical-stage biotechnology company developing treatments for neurodegenerative diseases, including ALS, Alzheimer's, and Parkinson's.

• Lead candidate PrimeC is an extended-release oral combination of ciprofloxacin and celecoxib, targeting ALS pathology via multiple mechanisms.

• PrimeC has orphan drug designation from FDA and EMA, and SME status from EMA.

• Positive results from Phase 2b PARADIGM trial, with plans for a pivotal Phase 3 study in ALS starting H2 2025.

• Pipeline includes additional candidates for Alzheimer's (CogniC) and Parkinson's (StabiliC), following a similar combined-therapy approach.

Financial performance and metrics

• As of June 30, 2025, pro forma cash was $4.1 million, with pro forma as adjusted cash of $10.4 million after the offering.

• Accumulated deficit as of June 30, 2025, was $41.4 million.

• Pro forma as adjusted total capitalization after the offering is $9.2 million.

• Audit report includes a going concern warning due to recurring losses and expectation of significant additional losses.

Use of proceeds and capital allocation

• Net proceeds will fund clinical development of PrimeC for ALS, preclinical and clinical work for CogniC (AD) and StabiliC (PD), new product candidates, working capital, and general corporate purposes.

• Management retains broad discretion over allocation of proceeds.